About pSivida
pSivida is a publicly listed company based in Watertown (United States) founded in 1987. Drug delivery systems. The company has 49 employees. pSivida has completed 1 acquisition, including EyePoint Pharmaceuticals. Its chief executive, as recorded, is Paul Ashton. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is PSIVIDA CORP. Its competitors include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 1987 and based in Watertown, United States, pSivida operates in the biotechnology sector, focusing on sustained-release drug delivery technologies. Products such as Durasert and Tethadur are licensed to partners including Pfizer and Alimera Sciences for applications in ophthalmology. FDA-approved offerings like ILUVIEN for diabetic macular edema and Retisert for uveitis are utilized through intravitreal implants, with administration controlled for months or years.
- Headquarters Watertown, United States
- Employees 49
- Stage Public
- SectorsHealthcare
- Website psivida.com
- Social LinkedIn X
- Legal Name Psivida Corp.
- Annual Revenue$3.1 M (USD)210as on Dec 31, 2024
- Net Profit-$130.87 M (USD)-85as on Dec 31, 2024
- EBITDA-$145.85 M (USD)-94as on Dec 31, 2024
- Latest Funding Round$60.5M (USD), Post-IPO
Mar 2018
- InvestorsRA Capital
& 2 more
- Employee Count49
- Investments & Acquisitions
Funding Insights of pSivida
- Total Rounds 4
- Last Round Post-IPO β $60.5M
- First Round $40M
(Jul 2012)
- Investors Count 3
All 4 funding rounds of pSivida with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $20M | Debt – Conventional | β | β | |
| Mar 2018 | $60.5M | Post-IPO | β | β | |
| Mar 2014 | $7M | Post-IPO | β | β | |
| Jul 2012 | $40M | Post-IPO | β | β | β |
3 investors in total: 3 institutional.
Investors in pSivida
pSivida has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, SWK Holdings and EW Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Investments and advisory services are provided by the holding company. | 2009 | swkhold.com | Dallas, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for pSivida
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of pSivida
87 people are tracked at pSivida (44 in leadership, 14 in board & advisors, 29 in team); the tracked headcount is 49.
| Name | Role | Group |
|---|---|---|
Paul Ashton | CEO | Leadership |
Bridget Eastes | Controller, Director | Leadership |
Erika Boucher | IT Business Relationship Director | Leadership |
Ramiro Ribeiro | Chief Medical Officer | Leadership |
Joseph Clements | Senior Director Quality Control | Leadership |
Raj Dasari | Sr. Director, Validation Engineering | Leadership |
Brian Burke-Green | Associate Director Regulatory Submissions | Leadership |
Keyur Patel | Vice President, Head Medical Affairs | Leadership |
Monica Roy | Vice President, Clinical Development -ophthalmology | Leadership |
Jennifer Leonard | Chief People Officer & SVP, IT | Leadership |
Jay S. Duker | President & CEO | Leadership |
George O. Elston | CFO & Head of Corporate Development | Leadership |
Isabelle Lefebvre | Chief Regulatory Officer | Leadership |
Christine Greenough | Senior Director , Global Quality Assurance | Leadership |
Rich Welch | Associate Director, Application Support | Leadership |
Ron Honig | Chief Legal Officer & Company Secretary | Leadership |
Scott Jones | Chief Commercial Oficer | Leadership |
Theresa Dibiase | Associate Director, Talent Acquisition | Leadership |
Craig Chatham | Head Of Financial Planning And Analysis And Financial Systems | Leadership |
Joe Musiak | Senior Director, Facilities & Engineering | Leadership |
67 more people are available in the full profile.
Complete people profiles for pSivida
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by pSivida
pSivida has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EyePoint Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for ophthalmic disorders are developed. | eyepointpharma.com | Watertown, United States | 1987 | Mar 2018 | $55M |
Complete acquisition details for pSivida
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of pSivida
5 dated milestones of pSivida across 31 years, from founding to its latest funding, stage changes and deals.
- Founded pSivida is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $40.0M.
- Funding Latest funding round, Post-IPO, of $60.5M.
- Acquisition Acquires EyePoint Pharmaceuticals.
Competitors of pSivida
pSivida has 3 listed competitors in our database, 1 of them funded. They include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | ||
| avicedarx.com | 2018 | Cambridge, United States | $254.66M | Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas. | ||
| eyepointpharma.com | 1987 | Watertown, United States | 49 | Small molecule therapeutics for ophthalmic disorders are developed. |
Detailed competitors of pSivida
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of pSivida
Websites that share an audience with pSivida (psivida.com).
Websites whose visitors overlap most with pSivida. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
neuralstem.com | neuralstem.com | 100% | β | ||
| alimerasciences.com | 96% | View details | |||
novartis.net | novartis.net | 92% | β | ||
| ethypharm.com | 92% | 3.5K | #6,712,435 | View details | |
retinavitreous.com | retinavitreous.com | 60% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for pSivida
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as pSivida (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Psivida
Complete news archive for pSivida
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about pSivida
pSivida was founded in 1987 and raised its 1st funding round 25 years after it was founded.
pSivida is headquartered in Watertown, United States.
Paul Ashton is the CEO of pSivida, as recorded in our data.
pSivida has 49 employees.
Annual revenue of pSivida is $3.1M as on Dec 31, 2024.
Founded in 1987 and based in Watertown, United States, pSivida operates in the biotechnology sector, focusing on sustained-release drug delivery technologies. Products such as Durasert and Tethadur are licensed to partners including Pfizer and Alimera Sciences for applications in ophthalmology. FDA-approved offerings like ILUVIEN for diabetic macular edema and Retisert for uveitis are utilized through intravitreal implants, with administration controlled for months or years.
pSivida's top competitors include EyePoint Pharmaceuticals, Rezolute and Aviceda Therapeutics.
pSivida has made 1 acquisition, including EyePoint Pharmaceuticals.
pSivida has 3 investors. Key investors include RA Capital, SWK Holdings, and EW Healthcare Partners.
pSivida operates through Psivida Corp..

